tiprankstipranks
Argent BioPharma Secures Funding for Drug Development
Company Announcements

Argent BioPharma Secures Funding for Drug Development

Argent Biopharma (AU:RGT) has released an update.

Don't Miss Our Christmas Offers:

Argent BioPharma has secured A$200,000 through the issuance of 666,667 shares at A$0.30 each, a strategic move aimed at advancing their drug development projects, including CannEpil® and CimetrA®, in the US and EU markets. This share placement comes at a discount, potentially offering investors an attractive entry point into the company’s growth journey. With this funding, Argent BioPharma continues to strengthen its position within the biopharmaceutical sector.

For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskArgent Biopharma to Delist from London Stock Exchange
TipRanks UK Auto-Generated NewsdeskArgent BioPharma to Delist from London Stock Exchange
TipRanks UK Auto-Generated NewsdeskArgent Biopharma Gains Strong Shareholder Support
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App